Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies
- PMID: 26551415
- DOI: 10.2217/fon.15.252
Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies
Abstract
The risk of secondary solid malignancies is increased after allogeneic hematopoietic stem cell transplantation (HSCT). The risk starts at about 10 years after HSCT and continues even 20 years later. The most common secondary malignancies include squamous cell carcinoma of skin, genitourinary tract and oral cavity; lung and breast cancers. The use of total body irradiation or conditioning chemotherapy, chronic graft-versus-host disease and duration since HSCT can influence the risk of secondary solid malignancies. Secondary solid malignancies are common causes of nonrelapse mortality in long-term survivors and may account for up to 10% of late deaths. Avoiding smoking, alcohol use and excess sun exposure may reduce the risk. Cancer prevention guidelines are largely consensus-driven and follow the recommendations for general population.
Keywords: allogeneic hematopoietic stem cell transplantation; prevention; risk factors; secondary solid malignancy.
Similar articles
-
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.Ann Oncol. 2014 Feb;25(2):435-41. doi: 10.1093/annonc/mdt558. Epub 2014 Jan 7. Ann Oncol. 2014. PMID: 24399081
-
High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.Bone Marrow Transplant. 2011 Apr;46(4):567-72. doi: 10.1038/bmt.2010.163. Epub 2010 Jul 12. Bone Marrow Transplant. 2011. PMID: 20622906
-
Second Malignancies after Hematopoietic Stem Cell Transplantation.Curr Treat Options Oncol. 2018 Feb 8;19(2):9. doi: 10.1007/s11864-018-0528-y. Curr Treat Options Oncol. 2018. PMID: 29423555 Review.
-
Secondary solid malignancies in long-term survivors after total body irradiation.Radiat Oncol. 2024 Sep 17;19(1):122. doi: 10.1186/s13014-024-02520-8. Radiat Oncol. 2024. PMID: 39289692 Free PMC article.
-
Oral malignancies following HSCT: graft versus host disease and other risk factors.Oral Oncol. 2005 Oct;41(9):865-77. doi: 10.1016/j.oraloncology.2005.02.001. Epub 2005 Apr 14. Oral Oncol. 2005. PMID: 16084755 Review.
Cited by
-
Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies.Strahlenther Onkol. 2022 Jun;198(6):547-557. doi: 10.1007/s00066-022-01914-5. Epub 2022 Mar 22. Strahlenther Onkol. 2022. PMID: 35318487 Free PMC article.
-
Oral chronic GVHD after allogeneic stem cell transplantation without total body irradiation performed at a young age.Support Care Cancer. 2022 May;30(5):4121-4128. doi: 10.1007/s00520-022-06836-7. Epub 2022 Jan 24. Support Care Cancer. 2022. PMID: 35075489 Free PMC article.
-
In MDS, is higher risk higher reward?Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):381-390. doi: 10.1182/hematology.2019000042. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808894 Free PMC article. Review.
-
Oral Dysplastic Complications after HSCT: Single Case Series of Multidisciplinary Evaluation of 80 Patients.Life (Basel). 2020 Oct 9;10(10):236. doi: 10.3390/life10100236. Life (Basel). 2020. PMID: 33050268 Free PMC article.
-
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.Transplant Cell Ther. 2025 Jun;31(6):347.e1-347.e17. doi: 10.1016/j.jtct.2025.01.885. Epub 2025 Jan 22. Transplant Cell Ther. 2025. PMID: 39855565
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources